Lauren Seeberger, MD

Clinical Professor, Neurology


FacultyPhoto
Medical School
  • MD, University of Alabama School of Medicine (1988)
Undergraduate School
  • BS, Vanderbilt University (TN) (1984)
Residency
  • Vanderbilt University Medical Center Program, Chief Resident, Neurology (1992)
Fellowships
  • UMDNJ-Robert Wood Johnson Medical School Program, Movement Disorders (1994)
Languages
English
Department
Neurology

Professional Titles

  • Director, University of Colorado Movement Disorders Center
  • Director, University of Colorado Movement Disorders Center Fellowship program

Research Interests

My research has focused on clinical testing of new medications to treat or slow progression of movement disorders and in new uses for already approved medications.

Publications

  • Seeberger LC, Hauser RA. Carbidopa levodopa enteral suspension. Expert Opin Pharmacother. 2015 Dec;16(18):2807-17. PubMed PMID: 26595228
  • McGarry A, McDermott M, Kieburtz K, de Blieck EA, Beal F, Marder K, Ross C, Shoulson I, Gilbert P, Mallonee WM, Guttman M, Wojcieszek J, Kumar R, LeDoux MS, Jenkins M, Rosas HD, Nance M, Biglan K, Como P, Dubinsky RM, Shannon KM, O'Suilleabhain P, Chou K, Walker F, Martin W, Wheelock VL, McCusker E, Jankovic J, Singer C, Sanchez-Ramos J, Scott B, Suchowersky O, Factor SA, Higgins DS Jr, Molho E, Revilla F, Caviness JN, Friedman JH, Perlmutter JS, Feigin A, Anderson K, Rodriguez R, McFarland NR, Margolis RL, Farbman ES, Raymond LA, Suski V, Kostyk S, Colcher A, Seeberger L, Epping E, Esmail S, Diaz N, Fung WL, Diamond A, Frank S, Hanna P, Hermanowicz N, Dure LS, Cudkowicz M. A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology. 2016 Dec 2. [Epub ahead of print] PubMed PMID: 27913695
  • Seeberger LC, Hauser RA. Carbidopa levodopa enteral suspension. Expert Opin Pharmacother. 2015;16(18):2807-17. PubMed PMID: 26595228
  • Biglan KM, Shoulson I, Kieburtz K, Oakes D, Kayson E, Shinaman MA, Zhao H, Romer M, Young A, Hersch S, Penney J, Marder K, Paulsen J, Quaid K, Siemers E, Tanner C, Mallonee W, Suter G, Dubinsky R, Gray C, Nance M, Bundlie S, Radtke D, Kostyk S, Baic C, Caress J, Walker F, Hunt V, O'Neill C, Chouinard S, Factor S, Greenamyre T, Wood-Siverio C, Corey-Bloom J, Song D, Peavy G, Moskowitz C, Wesson M, Samii A, Bird T, Lipe H, Blindauer K, Marshall F, Zimmerman C, Goldstein J, Rosas D, Novak P, Caviness J, Adler C, Duffy A, Wheelock V, Tempkin T, Richman D, Seeberger L, Albin R, Chou KL, Racette B, Perlmutter JS, Perlman S, Bordelon Y, Martin W, Wieler M, Leavitt B, Raymond L, Decolongon J, Clarke L, Jankovic J, Hunter C, Hauser RA, Sanchez-Ramos J, Furtado S, Suchowersky O, Klimek ML, Guttman M, Sethna R, Feigin A, Cox M, Shannon B, Percy A, Dure L, Harrison M, Johnson W, Higgins D, Molho E, Nickerson C, Evans S, Hobson D, Singer C, Galvez-Jimenez N, Shannon K, Comella C, Ross C, Saint-Hilaire MH, Testa C, Rosenblatt A, Hogarth P, Weiner W, Como P, Kumar R, Cotto C, Stout J, Brocht A, Watts A, Eberly S, Weaver C, Foroud T, Gusella J, MacDonald M, Myers R, Fahn S, Shults C. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. JAMA Neurol. 2016 Jan;73(1):102-10. PubMed PMID: 26569098
  • Seeberger LC. “Dysgeusia”, in: The Five Senses and Beyond: The Encyclopedia of Perception. Edited by: Hellier, JL. Greenwood. November 2016.
  • Seeberger LC, Hauser RA. Valbenazine for the treatment of tardive dyskinesia. Expert Opin Pharmacother. 2017 Aug;18(12):1279-1287. PubMed PMID: 28699794
  • McGarry A, McDermott M, Kieburtz K, de Blieck EA, Beal F, Marder K, Ross C, Shoulson I, Gilbert P, Mallonee WM, Guttman M, Wojcieszek J, Kumar R, LeDoux MS, Jenkins M, Rosas HD, Nance M, Biglan K, Como P, Dubinsky RM, Shannon KM, O'Suilleabhain P, Chou K, Walker F, Martin W, Wheelock VL, McCusker E, Jankovic J, Singer C, Sanchez-Ramos J, Scott B, Suchowersky O, Factor SA, Higgins DS Jr, Molho E, Revilla F, Caviness JN, Friedman JH, Perlmutter JS, Feigin A, Anderson K, Rodriguez R, McFarland NR, Margolis RL, Farbman ES, Raymond LA, Suski V, Kostyk S, Colcher A, Seeberger L, Epping E, Esmail S, Diaz N, Fung WL, Diamond A, Frank S, Hanna P, Hermanowicz N, Dure LS, Cudkowicz M. A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology. 2017 Jan 10;88(2):152-159. PubMed PMID: 27913695
  • Zesiewicz TA, Sullivan KL, Ponce de Leon M, Bennett A, Hohler AD. Quality improvement in neurology: Essential Tremor Quality Measurement Set. Neurology. 2017 Sep 19;89(12):1291-1295. PubMed PMID: 28835402
  • Piquet AL, Khan M, Warner JEA, Wicklund MP, Bennett JL, Leehey MA, Seeberger L, Schreiner TL, Paz Soldan MM, Clardy SL. Novel clinical features of glycine receptor antibody syndrome: A series of 17 cases. Neurol Neuroimmunol Neuroinflamm. 2019 Sep;6(5):e592. PubMed PMID: 31355325
  • Leehey MA, Liu Y, Hart F, Epstein C, Cook M, Sillau S, Klawitter J, Newman H, Sempio C, Forman L, Seeberger L, Klepitskaya O, Baud Z, Bainbridge J. Safety and Tolerability of Cannabidiol in Parkinson Disease: An Open Label, Dose-Escalation Study. Cannabis Cannabinoid Res. 2020;5(4):326-336. PubMed PMID: 33381646
  • Brownstein MJ, Simon NG, Long JD, Yankey J, Maibach HT, Cudkowicz M, Coffey C, Conwit RA, Lungu C, Anderson KE, Hersch SM, Ecklund DJ, Damiano EM, Itzkowitz DE, Lu S, Chase MK, Shefner JM, McGarry A, Thornell B, Gladden C, Costigan M, O'Suilleabhain P, Marshall FJ, Chesire AM, Deritis P, Adams JL, Hedera P, Lowen K, Rosas HD, Hiller AL, Quinn J, Keith K, Duker AP, Gruenwald C, Molloy A, Jacob C, Factor S, Sperin E, Bega D, Brown ZR, Seeberger LC, Sung VW, Benge M, Kostyk SK, Daley AM, Perlman S, Suski V, Conlon P, Barrett MJ, Lowenhaupt S, Quigg M, Perlmutter JS, Wright BA, Most E, Schwartz GJ, Lamb J, Chuang RS, Singer C, Marder K, Moran JA, Singleton JR, Zorn M, Wall PV, Dubinsky RM, Gray C, Drazinic C. Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial. J Clin Med. 2020 Nov 16;9(11). PubMed PMID: 33207828
  • Deuel LM, Seeberger LC. Complementary Therapies in Parkinson Disease: a Review of Acupuncture, Tai Chi, Qi Gong, Yoga, and Cannabis. Neurotherapeutics. 2020 Aug 12. [Epub ahead of print] PubMed PMID: 32785848

Professional Memberships

  • American Academy of Neurology, Fellow Member
  • International Parkinson and Movement Disorder Society, Member

Practice Locations

UCHealth Neurosciences Center - Anschutz Medical Campus
1635 Aurora Ct
4th Floor
Aurora, CO 80045
720-848-2080

UCHealth Anschutz Outpatient Pavilion - Anschutz Medical Campus
1635 Aurora Ct
Aurora, CO 80045
720-848-0000

Hospital Affiliation
  • University of Colorado Hospital
  • Children's Hospital Colorado
  • Denver Health Medical Center

Center Affiliations

Specialty Information

Specialties
  • Neurology, Board Certification (1994)
  • Movement Disorders, Specialized Training (0001)
Conditions & Treatments
  • Brain and Nervous System - Deep Brain Stimulation
  • Brain and Nervous System - Parkinson's Disease
  • Brain and Nervous System
  • Brain and Nervous System - Movement Disorders
Clinical Interests
I am a board-certified neurologist specializing in Movement Disorders. I completed neurology residency at Vanderbilt University and a two-year fellowship at Robert Wood Johnson-University of Medicine and Dentistry New Jersey. I provide treatment and care for patients with Parkinson disease, Parkinson plus syndromes, Lewy Body disease, Huntington’s disease, dystonia, Tourette, tics, chorea, ataxia, Restless leg Syndrome, myoclonus, drug-induced movement disorders, Essential Tremor, and tremor. I have long-standing expertise in the use of botulinum toxins for neurological conditions. I also have expertise in the use of deep brain stimulation for Parkinson disease, essential tremor, and dystonia. My research focuses on clinical testing of new medications to treat or slow the progression of movement disorders. I also study new use for medications that are already approved.